XML 69 R58.htm IDEA: XBRL DOCUMENT
v3.21.2

Note 12 - Segment Information - Operating Segment Asset Reconciliation (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Mar. 31, 2021 | Mar. 31, 2020
--- | --- | --- | ---
Total inventories | $ 12,117 | $ 11,178 | $ 11,178
Operating Segments [Member] | Sterilization and Disinfection Control [Member] |  |  |
Total inventories | 2,187 | 2,333 |
Operating Segments [Member] | Biopharmaceutical Development [Member] |  |  |
Total inventories | 3,706 | 4,162 |
Operating Segments [Member] | Instruments [Member] |  |  |
Total inventories | 4,566 | 3,253 |
Operating Segments [Member] | Continuous Monitoring [Member] |  |  |
Total inventories | $ 1,658 | $ 1,430 |

X
- Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_InventoryNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_ContinuousMonitoringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |